Comparison of the effects of Fluticasone, Boutsonide, and Mometasone sprays on patients with nasal-sinus polyposis after sinus endoscopic surgery

Document Type : Original Article

Author

Department of Otorhinolaryngology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

10.22034/mbt.2022.328473.1010

Abstract

As inflammation of the lining of the nose and sinuses, chronic rhinosinusitis significantly affects patients’ daily functioning, mental health, and quality of life. Inflammatory disorders and anatomical problems are known as some of the causes of this condition. Topical and systemic corticosteroids are widely used to treat various chronic inflammatory diseases. Given the high prevalence and impact of the disease on patients’ quality of life, this study compared the effects of fluticasone, budesonide, and mometasone sprays among patients with nasal-sinus polyposis after sinus endoscopic surgery. In this study, 225 patients suffering from chronic rhinosinusitis with polyposis were randomly assigned to three groups. The groups received 0.1 mg fluticasone nasal spray, 0.1 mg budesonide spray, and 0.1 mg mometasone spray for six months. Patients completed the sino-nasal outcomes test-22 (SNOT-22) questionnaire at the time of admission and six months after taking the drug. Data were analyzed in SPSS software version 16 using the ANOVA, Kruskal–Wallis, Chi-square, and Fisher’s exact tests. The level of significance was set at α = 0.05. The frequency distribution of different dimensions of the SNOT-22 questionnaire at baseline and end of the study was not significantly different between the two groups (P>0.05). The mean total scores of the SNOT questionnaire at baseline (P=0.289) and end of the study (P=0.063) were not significantly different between the three groups. Fluticasone, budesonide, and mometasone sprays did not exert significantly different impacts on the symptoms of nasal polyps, and their effectiveness was identical.

Keywords


  • Receive Date: 12 October 2021
  • Revise Date: 21 November 2021
  • Accept Date: 11 December 2021
  • First Publish Date: 11 December 2021